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Abstract
Purpose: Burkitt lymphoma (BL) is a highly aggressive mature B-cell non-Hodgkin lymphoma (NHL) and is the fastest growing
human tumor. The outcome of childhood NHL has improved steadily over the past decades through the use of intensive se-
quential multi-agent chemotherapy regimens. Methods: A retrospective study having all patients 18 years old or younger diag-
nosed with mature B cell NHL and treated at Children Cancer Hospital Egypt (CCHE). All children were treated according to
the modified (LMB 96) protocol during the period between July 2007 and December 2012. Patients were followed up till June
2013. Results: Three hundred and seventy-seven patients were diagnosed with mature B cell NHL and received the LMB96
treatment protocol. The majorities were males (76.4%) with a median age of 5.3 years, and ranged from 0.1-18.0 years. The me-
dian follow-up period was 28.2 months (range 0.9-72 months). Burkitt lymphoma was the most predominant pathologic subtype
(79.6%, n = 300), and abdominal mass as a primary site was the most common presentation (71.3%). Twenty seven patients
(7.2%) were treated as group A, 268 (71.0%) as group B, and 82 (21.8%) patients as high risk group C. Seventy-one (18.8%) pa-
tients suffered adverse events. Major adverse events were early deaths in 17 patients (4.5%), death during induction chemo-
therapy seen in 18 patients (4.7%), and during maintenance therapy in 7 patients (1.8%), tumor progression in 19 patients
(5.0%), and relapse in 10 patients (3.7%). Sixty-three patients (16.7%) died during the study period. The main causes of death
were tumor lysis syndrome (TLS) in 25.3%, and severe sepsis during chemotherapy in 41.3% of the patients. The 3 years OS and
EFS were 83.3% and 80.4% respectively for the whole groups of patients. OS and EFS were 100% for group A, and 87.5%±3.9%
and 85.9±4.3% for group B. For group C BM+/CNS- patients, OS was 55.62%±15.8%, and EFS of 53.8%±15.6%. For BM+/CNS+
patients, OS and EFS were 63.2%±21.76% and 57.9%±22.1% respectively. BM-/CNS+ patients had OS 72.4%±18.8% and EFS
67.6%±19.7% at 36 months. Conclusion: TLS and chemotherapy related toxicity remains a major challenge affecting the out-
come of pediatric mature B cell NHL. We identified bone marrow involvement as a risk factor affecting treatment outcome.
Aggressive supportive care measures are mandatory to avoid unacceptable high toxicity related mortality.
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Introduction
Burkitt lymphoma (BL) is a highly aggressive mature B-cell
non-Hodgkin lymphoma (NHL) and is the fastest growing
human tumor. BL represents 40% of all childhood NHL and
3-4% of all childhood malignancies diagnosed each year in
the USA.1, 2 Its annual incidence in Africa has been estimated
at 40-50 per million children younger than 18 years com-
pared to 8 cases per million in France, and 7 per million in
The Netherlands.3 The outcome of childhood NHL has im-
proved steadily over the past decades through the use of
intensive sequential multi-agent chemotherapy regimens. In
high-income countries, 5-year survival rates reaches 90% in
patients treated according to the LMB 96 or BFM protocols
4-8, while the therapy offered in oncology units in
low-income countries is not as aggressive, and outcome is
not as good.9 The aim of the current study is to report the
treatment outcome, overall survival (OS) and event free sur-
vival (EFS) of patients who received FAB LMB96 protocol at
the Pediatric Oncology Department, Children Cancer Hos-
pital- Egypt (CCHE) during a 5.5 years period. Also to report
about incidence of tumor lysis syndrome, relapse rate, treat-
ment related mortality and causes of death in these patients.
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Methods and Materials
A retrospective study having all pediatric patients diagnosed
with mature B cell NHL and treated at CCHE. All children
were treated according to the modified (LMB 96) protocol
during the period between July 2007 and December 2012,
and were followed up till June 2013. Approval by our insti-
tutional scientific committee and informed written consent
were obtained prior to starting chemotherapy.
Eligibility and risk stratification
Newly diagnosed children and adolescents (<18 years) with
mature B-cell NHL were included in our study. Diagnosis
was done according to the WHO classification and included
Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL), Dif-
fuse large B cell lymphoma (DLBCL), mediastinal large B-cell
lymphoma (MLBCL), and mature B-cell neoplasm not oth-
erwise specified (NOS).10 Staging was performed according to
Murphy’s classification.11
Risk classification according to LMB96 protocol was defined
as low risk group A with resected stage I and abdominal
completely resected stage II; high risk group C with bone
marrow disease (25% L3 blasts) or CNS disease defined by
one or more of the following: any L3 CSF blast, cranial nerve
palsy, clinical spinal cord compression, isolated intracerebral
mass, cranial or spinal parameningeal extension; and inter-
mediate risk group B, included all patients not eligible for
group A or C. Exclusions to study enrollment included se-
vere immunodeficiency syndromes, HIV positivity, previous
malignancy, or prior chemotherapy.
Treatment
Chemotherapy was given according to the FAB LMB96 pro-
tocol
Group A
Patients assigned to group A received two courses of cyclo-
phosphamide, vincristine, prednisone, and doxorubicin
(COPAD) without intrathecal (IT) chemotherapy.8
Group B
Patients received prophase cyclophosphamide, vincristine,
and prednisone (COP), followed by induction chemotherapy
consisting of two cycles of vincristine, prednisone, adriamy-
cin, methotrexate, cyclophosphamide and intrathecal injec-
tion (COPADM), and two courses of cytarabine, methotrex-
ate (CYM) as consolidation if they were in complete remis-
sion (CR) post first course of consolidation Patients with less
than a 20% response on day 7 of COP and patients with re-
sidual disease after CYM-1 were upgraded to group C starting
from CYVE1.12
Group C
Following prophase COP, patients had induction chemo-
therapy which consisted of two cycles of COPADM
(HD-MTX 8 g/m2) followed by consolidation with 2 cycles of
high-dose continuous infusion ofcytarabine plus etoposide
(CYVE). Patients with CNS disease received additional IT
therapy as well as an additional HD-MTX course between
consolidation courses. At last, 4 maintenance cycles, the first
consisted of COPADM, followed by three cycles with low
dose cytarabine and etoposide (cycles 2 and 4), with the third
cycle being similar to the first but without HDMTX and IT.13
Criteria of response
Complete response (CR) was defined as complete disappear-
ance of all tumor masses, partial response (PR; 20% - 99%
tumor reduction), no response (NR) or stable disease (SD);
<20% tumor reduction. Progressive disease (PD) was > 25%
increase in tumor size, while relapse was defined as recur-
rence of disease at any site after achieving CR. Failure was
considered as relapses, deaths and failures to achieve a CR
within the time frame.
Unresponsiveness to initial COP in itself was not considered
a failure of the treatment strategy. Patients in critical condi-
tion (renal failure, sepsis, grade III/IV organ toxicity) were
allowed to receive a second course of COP prior to proceed-
ing to induction.13
Statistical methods
Data was analyzed using the Statistical Package for Social
Sciences (SPSS) for Windows package version 15 (SPSS Inc.,
Chicago, Illinois, USA). Numerical data was presented as
mean ± standard deviation (SD), median and range. Qualita-
tive data was presented as numbers and percentages. Kaplan
Meier was used to estimate survival and Log rank test for
comparison. Overall survival (OS) was defined as the time
from diagnosis till the end of the study period or death,
while EFS was defined as the minimum period from diagno-
sis till the occurrence of an event including induction failure,
disease progression, relapse, second malignancy, lost FU or
death from any cause. A P -value ≤ 0.05 was considered sig-
nificant.
Results
Patients’ characteristics: out of the 530 patients diagnosed
with NHL between July 2007 and December 2012, 377
(71.2%) patients had mature B cell NHL and received the
LMB96 treatment protocol. There was a significant male
predominance with 288 male patients (76.4%) and 89 Fe-
males (23.6%). The median age was 5.3 years, and ranged
from 0.1-18.0 years. Number of patients varied in age group,
with the range from 0 to 4 years being the most common
(44.0%).
Demographic characteristics of study patients are summa-
rized in Table 1, while Table 2 shows common sites of CNS
involvement.
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TABLE 1: Initial characteristics of the 377 studied patients.
Frequency Percent
Age








Burkitt lymphoma (BL) 300 79.6
B-cell (L3) leukemia 54 14.3
DLBC 18 4.8
MLBCL 3 0.8
Mature B-NHL NOS 2 0.5
Primary site
Abdomen 269 71.3
Peripheral lymph nodes 121 32.0
Thorax (not primary MDLBC) 87 23.0
Head and neck 62 16.4
Other tumor site 12 3.1
Modified Murphy's staging
Stage I 18 4.8
Stage II 110 29.2
Stage III 167 44.3
Stage IV 28 7.4
ALL L3 54 14.3
Clinical Group
Group A 27 7.2
Group B 268 71.0
Group C 82 21.8
BM/CNS involvement
BM +/CNS- 41 50
BM-/CNS+ 22 26.8
BM+/CNS+ 19 23.2
BM= Bone marrow; DLBC= Diffuse large B-cell Lymphoma;
MLBCL= Mediastinal large B-cell lymphoma; NOS= Non Otherwise
specified; CNS= Central nervous system.
TABLE 2: Common sites of CNS involvement.
Total number Percentage
CNS involvement 41 10.9
Parameningeal extension 26 6.9




Cranial nerve palsy 5 1.3
Intra-orbital extension 1 0.3
CSF= Cerebrospinal fluid.
Burkitt lymphoma was the most predominant pathologic
subtype (79.6%, n = 300), while abdominal mass as a primary
site was the most common presentation (71.3%, n = 269).
According to the modified Murphy Staging, stage III was the
most common presentation seen in 167 patients (44.8%)
Table 1.
Tumor Lysis Syndrome (TLS)
Laboratory and/or clinical tumor lysis syndrome was ob-
served in 57 patients (15.1%); of which 30 (11.2%) out of 268
patients were group B, and 27(32.9%) out of 82 in group C.
Sixteen patients (4.2%) died out of TLS during the prophase
chemotherapy (COP). They represent most of the mortality
causes during this period of chemotherapy (16/17 = 94.1%).
Table 3 shows the major adverse events in studied patients.
Chemotherapy outcome
Following the LMB96 protocol risk stratification, 27 patients
(7.2%) treated as group A, 268 patients (71.0%) as group B,
and 82 patients (21.8%) in high risk group C.
Group A
All 27 patients stratified as group A (7.2%) received chemo-
therapy successfully, and are alive in CR.
Group B
Two hundred-sixty eight patients were stratified as group B.
Following initial COP course of chemotherapy; 218 (81.3%)
had >20% radiologic response and continued on same line.
Twelve patients (3.18%) died from severe sepsis and/or TLS
during prophase. Twenty eight patients (10.4%) didn't re-
ceive COP and started COPAM directly as they were con-
sidered to have no bulky tumor (stage II unresected tumor
and/or incomplete resection anastomosis of primary intesti-
nal mass). Ten patients (3.7%) had mild to no response de-
fined as less than 20% decrease in the initial tumor volume
and were upgraded to group C. Eight patients (2.9%) died
from sever sepsis during chemotherapy, 12 (4.4%) progres-
sion, and 8 (2.9%) relapses (Table 3).
Group C
Eighty two patients were treated as group C. They were 41
(10.8%) BM+/CNS-, 22 (5.08%) BM-/CNS+, and 19 patients
(5.0%) BM+/CNS+. Twenty two patients (5.8%) had treatment
related mortality, while 7 patients (1.8%) had tumor pro-
gression, and 2 patients (0.5%) relapsed.
Events, relapses and tumor progression
Seventy-one patients (18.8%) suffered adverse events, 40
(10.6%) in group B, and 31 (8.2%) in group C. There were no
events in group A patients. Major adverse events were early
deaths in 17 patients (4.5%), death during induction chemo-
therapy seen in 18 patients (4.7%), death during mainte-
nance therapy in 7 patients (1.8%), tumor progression in 19
patients (5.0%), and relapse in 10 patients (3.7%). Table 3
describes major events according to risk groups.
Survival
By the end of our study, 291 patients were alive in CR
(77.2%) while 63 patients (16.7%) died. Twenty patients
(5.3%) lost FU (5 patients; 1.3% in active disease, and 15
patients; 4.0% in CR) as shown in Table 4.
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TABLE 3: Adverse Events in patients with NHL.
Death Progression Relapse Total
Prophase Induction Consolidation
Group B 12 6 2 12 8 40
Group C 5 12 5 7 2 31
BM+/CNS- 3 5 2 3 1 14
BM-/CNS+ 1 2 1 1 1 6
BM+/CNS+ 1 5 2 3 0 11
Total 17 18 7 19 10 71
TABLE 4: Disease Status in the studied patients.
Disease Status
Frequency Percent
Alive in Active Disease 3 0.8
Alive in CR 291 77.2
Died in Active Disease 57 15.1
Died in CR 6 1.6
Lost Follow Up in Active Disease 5 1.3
Lost Follow Up in CR 15 4.0
The 3 years OS and EFS were 83.3% and 80.4% respectively for the whole group of patients Figures 1 and 2.
FIG. 1: Overall survival for all Patients (83.3%).
FIG. 2: Event-free survival for all patients (80.4%).
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FIG. 3: Overall survival in different group categories.
FIG. 4: Event free survival in different group categories.
OS and EFS were 100% for group A, and 87.5%±3.9% and
85.9±4.3% for group B. For group C BM+/CNS- patients, OS
was 55.62%±15.8%, and EFS of 53.8%±15.6%. For BM+/CNS+
patients, OS and EFS were 63.2%±21.76% and 57.9%±22.1%
respectively. BM-/CNS+ patients had OS 72.4%±18.8% and
EFS 67.6% ±19.7% at 36 months (Figure 3 and 4).
The mean FU period was 29.2 months (range 0.9 - 72
months), with an SD 19.2 months. Median FU period of all
patients was 28.2 months for all patients.
Discussion
This retrospective study describes the treatment outcome of
pediatric patients treated on the LMB-96 in our institute
during 5.5 years period. To the best of our knowledge, it’s
one of the largest single center patient’s series in the Middle
East region. Mean age of the patients is slightly lower than
many previous studies 5, 12, 14, but similar to our previous re-
port 15. Age category below 4 years was the most common in
the studied group in contrast to other study groups 13, 16, were
ages between 5-9 years being the most common, although
age is not considered as risk factor 17. Cairo et al. in 2012
identified advanced stage, increased LDH level > 2 X normal
value, mediastinal disease and combined BM+/CNS+ as the
main risk factors for treatment response.17 In our study,
analysis of prognostic factors including age, gender, upfront
tumor resection and CNS status were all statistically insig-
nificance. Nevertheless, BM involvement was found to be
associated with lower OS and EFS, but this difference was
statistically insignificant probably due to small sample size.
The obvious male predominance observed in the current
study is a common finding in pediatric mature B cell NH 5, 12,
13, 15-20. BL and B-ALL were the predominant pathologic
subtype followed by DLBC of the studied patients, but in
different ratio, as they represented 5% of the patients com-
pared to 14% 12, 10% 13, 11.7% 15, 14.9% 14 and 31.4% 16 of
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the patients in different studies. Other rare subtypes ob-
served were PMLBCL and mature B-NHL NOS.
In most studies reporting pediatric mature B cell NHL
-including the present one- abdominal mass, stage III, group
B were the most common presentation, followed by periph-
eral lymph enlargement including head and neck regions,
mediastinal mass, CNS involvement but with different inci-
dences according to the studies.5, 12, 14, 15-17, 20
In the current study, 15.1% of the patients had laboratory
and/or clinical TLS, representing 11.1% of group B and
32.9% of group C patients reflecting its increased incidence
in close association with tumor aggressiveness. Management
of TLS was done using the administration aggressive hydra-
tion and allopurinol as non-recombinant urate oxidase is not
available routinely in our country. In previous, studies la-
boratory TLS incidence ranged from 27% to 42% of the pa-
tients 21-24, although clinical TLS incidence is much lower
ranging from 4.4% to 8.4% 21-23.
Stage I disease represented 4.8%, stage II 29.1%, stage III
44.8%, stage IV 21.7%, while L3 ALL were 14.3%. Similarly,
few authors reported the same incidence in stage I 5, 15, 20, and
stage III disease 5, 14, 17, 20. Our results are higher in stage II
compared to few reports.5, 15, 17On the other hand, we report
lower incidence in stage IV disease 5, 15-17, 20and L3 ALL than
some studies5, 16.
Low risk group A patients represented 7.2% compared to
71.0% group B and 21.8% for high risk group C patients. In
group A patients, incidence is in concordance with Patte et
al.5, and higher than our previous report 15, this is probably
be due to accumulation of experience and better risk stratifi-
cation. In group B and C patients, similar incidence was re-
ported in the literature.5, 15, 17 Reiter et al. reported different
incidence: 17% in R1, 40% in R2 and 43% in R3 group of
patients but with a risk stratification based on tumor resec-
tion, LDH level, and localization of the primary tumor.14 In
our study, LDH was not considered as it was not part of the
risk stratification.
Following initial cytoreductive chemotherapy, 90.8% of the
patients were good responders and continued as group B,
while 3.7% were upgraded to group C. Patte et al. reported
95% response to prophase treatment 5, 12 and 4.9% 12, 4.5% 5
as non-responders. We previously reported a similar re-
sponse rate.15 Ten percent of the patients underwent incom-
plete resection of their abdominal mass, or had small initial
tumor size, hence we estimated no need for cytoreductive
course of chemotherapy and they received COPADM1 di-
rectly.
We report a high mortality rate (16.7%) in our study when
compared to 7.3% reported in FAB LMB 89 study 5, 3.3% in
NHL-BFM 90 study 15, 4.6 % in LMB 96 high risk patients 13.
Another large-scale study resulted in a cure rate above 90%
with a 7.7% mortality rate, and <1% toxic death in child-
hood B-NHL.16
Analyzing this high mortality rate, out of 16.7% died during
therapy; 4.2% died directly or indirectly due to TLS, 6.9%
out septicemia during chemotherapy, and 5.3% due to tumor
progression. Again, this very high induction mortality rate
was due to sepsis following grade IV neutropenia. Reiter et
al. reported 3.3% deaths from different causes including
acute TLS, toxic death or infection, but none during the
course of chemotherapy14, while Patte et al. reported 7.3% 12.
Deaths during induction period (28%) were mostly following
COPADM1 course, probably due to accumulated hemato-
logic toxicity of the two courses given in short duration,
while high dose Ara-C and related toxicity was the main
cause of death during consolidation (11%) in group C pa-
tients. Similarly, life threatening infections were reported
during COPADM1 and CYVE 5, 25. Other causes of death
were tumor progression in 10% of the patients.
Our 3-years OS and EFS were 83.3% and 80.4% respectively.
The current results are similar to what we have reported
previously 15, but are worse than most of the studies using
similar protocols or multi-drug combination. Patte et al.
reported 5 years OS 92.5% and EFS 91% in 2001.5 Six years
EFS 89% + 2% was reported by Reiter et al. 14, while 3 years
EFS was 88% + 1% was reported by Cairo et al.17 A recent
Japanese study reported 4 years OS and EFS were 92.7% and
87.4% respectively16. For group A patients, we confirm our
excellent results obtained previously.15 The same is reported
by most of the study groups that resected stage I and ab-
dominal stage II have excellent prognosis regardless of the
chemotherapy regimen given5, 12, 14, 16. Four years EFS report-
ed by Gerrad et al. was 98.3%, while OS was 99.2%.8 OS and
EFS for low risk patients were between 98% to 100% in most
of the studies.5, 14-17
For group B patients, OS and EFS were 87.5%±4.1% and
85.9%±4.3% respectively, lower than most studies performed
as 92% 5, 12, 96% 14, 89% 17, and 93.6% 16. This could be ex-
plained by high rate of chemotherapy related mortality
(11.1%), as relapse rate and disease progression in our study
(8.7%) were not higher than any study group report.12, 14, 16
Fifty percent of group C patients in our study were BM+,
while 26% had CNS involvement and 24% were both BM+
and CNS+. Similar incidence rate was reported.5, 13-16
Our worst results are in high risk group C BM+/CNS-, and
BM+/CNS+ patients. OS was 55.62%±15.8% and 63.2%±21.76
% respectively, while EFS was 53.8%±15.6% and 57.9%±
22.1% respectively. The sub-group of patients with BM in-
volvement at diagnosis was associated with poor outcome,
compared to CNS involvement. To the contrary of most of
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the studies, combined BM+ and CNS+, or those with CNS+
disease had the worst outcome 5, 13, 16, 17, 26-29 and B-ALL had
excellent overall survival; 88% 5, 13, 14, 27, 28, and 86.2%+4.0%
16. This might be due to the fact that patients with BM in-
volvement express more hematologic toxicity and therapy
related mortality.
Patte et al. identified CNS involvement as the only prognos-
tic factor in group C patients.5 Similar conclusion was re-
ported by most of the study groups.13, 14, 16, 17, 25
Conclusion
In conclusion, chemotherapy related toxicity remains a ma-
jor challenge affecting the outcome of pediatric mature B cell
NHL. We identified BM involvement, and treatment related
toxicity during prophase/induction period of treatment as
risk factors affecting outcome. Aggressive supportive care
measures are mandatory to avoid unacceptable high toxicity
related mortality.
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